Mixed lineage leukemia (MLL) spanning KM2TA abnormalities, and newly incorporated ELN-2022 AML with myelodysplasia-related changes (AML-MRC) such as BCOR, constitutes an adverse risk AML. The gene discussed is KMT2A; the disease is acute myeloid leukemia.